Tissuegraft

What Tissuegraft does

Tissuegraft is a privately held, for-profit company founded in 2014 and headquartered in Alessandria, Italy. According to the firmographic data available, it develops biological matrices with biocompatibility for research applications, indicating a focus on biomaterial substrates intended for use in scientific and laboratory research settings rather than direct clinical or therapeutic deployment. The company operates at micro-scale, with a reported headcount band of 1–10 employees, and maintains a web presence at tissuegraft.it.

No further operational detail is available from the aggregated sources. The company's website resolves to a generic loading/verification page rather than substantive commercial content, and no product catalog, pricing model, customer references, partnership network, management team, regulatory filings, funding history, or revenue figures are disclosed. No patents, certifications, awards, social profiles, or distribution channels are recorded. As a result, the business model — including how Tissuegraft monetizes its biological matrices, which customer segments it serves beyond the broad "research applications" label, and what its go-to-market motion looks like — cannot be characterized from the input data. This represents a significant information gap that limits investment diligence to the high-level firmographic anchors noted above.

Name

Tissuegraft

Website

https://tissuegraft.it

Company type

Private

Founded year

2014

Headcount range

1–10 employees

Short description

Tissuegraft is a privately held Italian biotech founded in 2014 that develops biocompatible biological matrices for research applications. The micro-scale firm (1–10 employees) is based in Alessandria, Italy, with no disclosed products, customers, or revenue.

Ownership category

akta.pro rank

Product category

Tissue Engineering Biomaterials

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), 3D Bioprinting & Biofabrication (HLAAAGAC)

Keywords

• Biological matrices
• Tissue engineering
• Biocompatible materials
• Research biomaterials
• Regenerative medicine

Headquarters

HQ city

Alessandria

HQ country

Italy

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain

Core offering

TissueGraft develops biological matrices with biocompatibility for research applications. The company produces biomaterial scaffolds intended to support cell growth and tissue-related studies in laboratory and pre-clinical research settings.

Differentiator

Problem solved

Functional benefit

Products and services

• Biological Matrices for Research

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Merck KGaA (Sigma-Aldrich): Merck's Sigma-Aldrich division offers a wide catalog of biomaterials, hydrogels, and scaffolds for life sciences research. Comparable to TissueGraft as a supplier of research-grade biocompatible matrices, though it operates as a broad-line catalog incumbent.
• Thermo Fisher Scientific: Thermo Fisher supplies Gibco-brand cell culture matrices, scaffolds, and 3D culture systems to research customers globally. Comparable to TissueGraft as a research-supply provider of biological matrices, but with vastly broader scale and product depth.
• Lonza Group: Lonza provides cell and gene therapy manufacturing tools including matrices and cell culture substrates used in research and commercial bioprocessing. Comparable to TissueGraft as a supplier of biological substrates for regenerative medicine research, though at far greater scale and with broader offerings.
• Corning Life Sciences: Corning's Life Sciences segment supplies a broad portfolio of extracellular matrices, scaffolds, and tissue culture substrates to research labs worldwide. Comparable to TissueGraft as a major research-grade matrix supplier, though it operates at vastly greater scale and across many product categories.

Direct peers

• CellGenix: CellGenix supplies cell culture reagents and matrices for cell and gene therapy manufacturing and research. Comparable to TissueGraft as a specialty supplier of biological matrices for research and translational applications.
• MatTek Life Sciences: MatTek develops tissue models and 3D reconstructed human tissue equivalents, including scaffold-based products used in research and regulatory testing. Comparable to TissueGraft as a small-to-mid specialty supplier of biological matrices and tissue constructs for research applications.
• REPROCELL: REPROCELL provides human tissue-derived products, stem cell technologies, and biological matrices for drug discovery and research applications. Comparable to TissueGraft as a specialty supplier of biological matrices for research markets.

Emerging players

• TissUse: TissUse develops multi-organ-on-chip platforms that rely on biological scaffolds and matrices to model human tissue interfaces. Comparable to TissueGraft as a downstream consumer/developer of biological matrices for advanced tissue research applications.
• InSphero: InSphero develops 3D microtissue models and scaffold-based organoids used in drug discovery and toxicology research. Comparable to TissueGraft in the niche of biological matrices and tissue constructs for research, though InSphero focuses on assay-ready microtissues rather than raw matrices.
• Cell Applications: Cell Applications supplies primary cells, biological matrices, and 3D culture tools to research customers. Comparable to TissueGraft as a specialty provider of biological substrates for cell biology and tissue engineering research.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tissuegraft